Bio Techne (TECH) Could Be 3% Overvalued As Recurring Revenue Supports The Story
Bio-Techne (TECH) continues to attract attention after recent trading left the share price near $72.69, with investors weighing its multi segment life sciences business against current market expectations for the stock.
Recent trading around $72.69 comes after a year where Bio-Techne delivered a 21.86% year to date share price return and a 17.87% total shareholder return over 12 months. However, longer term holders are still sitting on a 41.01% total return decline over five years, which points to improving momentum from a low base rather than a straight line recovery.
Scan how Bio-Techne fits beside other high quality life science and healthcare players by reviewing our hand picked list of solid balance sheet and fundamentals (24 results) for comparison.
For investors eyeing Bio-Techne after its rebound from much weaker five year returns, the real call now is simple: pay up at around $72.69 today or hold out for a cheaper entry as expectations reset.
Most Popular Narrative: 3% Overvalued
On the most followed view of Bio-Techne, the shares at $72.69 sit modestly above an implied fair value of about $70.73, which leaves the story hanging on how the business leans into its strongest franchises and the Merck deal.
High consumables mix of around 81% of sales provides a largely recurring revenue base across protein science, spatial biology, diagnostics and cell therapy. This can help smooth cyclical swings in instrument demand and support more stable cash flows and earnings.
See why 8 investors see Bio-Techne as 3% overvalued.
Result: Fair Value of $70.73 (OVERVALUED)
Still, if Protein Sciences weakness persists or organic growth continues to lag sector benchmarks, the Bio-Techne narrative could quickly shift from recovery to reset.
Find out about the key risks to this Bio-Techne narrative.
Next Steps
Curious whether the optimism in this Bio-Techne story matches your own read of the numbers and risks? Take a closer look at the upside signals in the 2 key rewards.
Looking for more Bio-Techne investment ideas?
If Bio-Techne has your attention, do not stop at a single ticker. Use focused screeners to surface other opportunities that match your standards and timing.
- Target potential mispricings by scanning a curated set of companies that combine strong fundamentals with appealing valuations through the 26 high quality undervalued stocks.
- Strengthen income potential by reviewing a pool of higher yielding payers with robust profiles using the 6 dividend fortresses.
- Dial down portfolio stress by filtering for resilient businesses with steadier risk characteristics inside the 32 resilient stocks with low risk scores.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com